Back to Search
Start Over
Hemispherx Biopharma Announces Identification of High Responder Patient Subgroup from Ampligen(R) Phase III Trial in Patients with CFS/ME
- Source :
- GlobeNewswire. October 31, 2016
- Publication Year :
- 2016
-
Abstract
- PHILADELPHIA, Oct 31, 2016 (GLOBE NEWSWIRE via COMTEX) -- 51% of patients in the high responder subset receiving Ampligen vs. 18% of placebo patients demonstrated improvement of at least 25% [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- GlobeNewswire
- Publication Type :
- News
- Accession number :
- edsgcl.468491889